Capivasertib is an AKT inhibitor designed for HR /HER2breast cancer patients with PIK3CA/AKT1/PTEN alterations. It works by stopping the AKT signaling pathway from doing its thing. You can get this med in tablet form—200 mg or a bigger 400 mg dose.
The typical amount to take is 400 mg, twice a day. You do 4 days on, then 3 days off. They come in bottles with 64 tablets.
